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rituximab, following the failure of one previous TNF inhibitor.
Upon treatment failure it was assumed patients would follow an
identical lifetime treatment strategy consisting of: leﬂunomide,
gold, cyclosporine and palliative care. As is currently recom-
mended by NICE no second TNF inhibitor was assumed to be
administered. Rituximab was assumed to be administered every
9 months for responding patients. ACR response rates were
taken from the respective phase III RCTs and adjusted for
placebo response. The initial HAQ drop by ACR category was
taken from the REFLEX RCT, with long-term HAQ progression
from published literature. RESULTS: Annual drug acquisition
and administration costs were lower for rituximab compared to
abatacept. Discounted total lifetime direct NHS costs were
£46,570 and £63,055 for the rituximab and abatacept groups
respectively. Rituximab generated a discounted cost-saving of
£16,485 per patient due to reduced drug acquisition and admin-
istration costs. Total QALYs were estimated as 3.879 and 3.812
for rituximab and abatacept, respectively. CONCLUSION: The
model predicted that rituximab dominated abatacept for RA
patients who have failed one previous TNF inhibitor therapy,
with higher estimated QALYs and lower NHS costs. Due to
lower drug administration requirements rituximab may also gen-
erate a capacity beneﬁt to the NHS compared with abatacept,
through lower annual infusion and outpatient requirements.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoim-
mune disorder associated with substantial health and economic
burden. We describe a cost-utility model developed to assess the
cost-utility of Abatacept in the treatment of RA in the UK (NHS).
METHODS: A probabilistic patient level simulation model was
developed to estimate long-term costs and health outcomes of
abatacept versus methotrexate (MTX) in RA patients who failed
anti-TNF therapy. The model predicted patients’ HAQ (Health
Assessment Questionnaire) scores over time based on the initial
response to treatment (% change in HAQ at six months).
Patients with an inadequate response (failure to achieve a speci-
ﬁed reduction in HAQ score) ended treatment at this point.
Responding patients continued treatment with a reduced rate of
HAQ progression until long-term treatment failure—modelled as
an exponential process. On long term treatment failure, patients’
HAQ was assumed to worsen by amount equal to their initial
improvement. Efﬁcacy and adverse events rates were obtained
from a randomized clinical trial. Costs, utility and annual mor-
tality rates (AMR) were estimated as a function of HAQ.
RESULTS: Compared to MTX, Abatacept treatment results in
1.6 additional QALYs at an additional cost of £40,371, giving an
ICER of £25,395/QALY, a value in line with other biologic
treatments recommended for use in the UK. Results were stable
under a range of sensitivity analyses. CONCLUSION: Compared
to MTX, Abatacept is a cost-effective treatment for patients who
failed anti-TNF therapy. The use of a patient level simulation
allows costs and utilities to be estimated as non-linear functions
of HAQ and for the AMR to be conditioned on patient’s HAQ
scores. The model was implemented in R and was sufﬁciently fast
for probabilistic analysis. This allowed two key requirements for
decision-making to be met: unbiased estimates of costs and
effects and an assessment of the decision uncertainty.
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OBJECTIVES: The targeted B-cell therapy rituximab (RTX) is
registered for patients with rheumatoid arthritis (RA) who have
had inadequate response or intolerance to one or more TNF-
alpha blocking agents. The only third payer in Hungary, the
National Health Insurance Found required economic data about
RTX treatment for reimbursement decision. The aim of our study
was to estimate the cost-effectiveness of RTX in Hungarian
context in RA patients who failed anti-TNF therapy.
METHODS: We developed a Markov model to perform a cost-
utility analysis. Cost per quality adjusted life year (QALY) gain
was assessed. RTX was compared with traditional treatment
(DMARDs) in the model. Model states were deﬁned by ACR
responses. Baseline characteristics of the patient population and
clinical efﬁcacy were based on international data, the REFLEX
trial. Costs of rituximab (drug therapy, administration and moni-
toring) were calculated based on ofﬁcial Hungarian price list. RA
related costs were taken from a previous Hungarian cost-of-
illness study considering disease levels by HAQ. Utility was
derived using the equation between HAQ and EQ-5D from a
Hungarian survey of RA patients. The time horizon of the model
was lifetime. Cost effectiveness analysis was performed for one
year RTX treatment. The model used a societal perspective
including all costs. RESULTS: One year long RTX treatment (9
month between courses) results in 0.228 QALY gain compared
with traditional treatment in lifetime perspective. Incremental
total costs were 6,224 Euros, cost-effectiveness ratio was 27,258
Euros/QALY. Cost-effectiveness of two years long RTX treat-
ment is 23,182 Euros/QALY. Increasing the duration of treat-
ment resulted better cost-effectiveness ratio. CONCLUSION:
Cost-effectiveness of RTX is under the commonly used ﬁnancing
threshold (30,000€/QALY), although RTX was compared with
low cost traditional treatment. Hungarian cost-effectiveness ratio
may be higher than the European average because drug costs are
comparable but medical costs are lower in Hungary than in the
EU.
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OBJECTIVES: Evaluate the impact of persistence with anti-TNF
treatment on total health care and medical costs among patients
with psoriatic arthritis (PsA). METHODS: A retrospective study
was conducted using the US PharMetrics managed-care-plan
database from January 2000 through June 2005. Patients con-
tinuously enrolled for 6 months pre- and 12 months post-index
biologic date and having 2 distinct claims for PsA were included.
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